Lyell Immunopharma vs IBM

Side-by-side comparison of AI visibility scores, market position, and capabilities

IBM leads in AI visibility (80 vs 24)

Lyell Immunopharma

EmergingBiotechnology

Cell Therapy

Lyell Immunopharma develops next-generation CAR-T cell therapies designed to overcome T cell exhaustion and treat solid tumors, the frontier of cell therapy.

AI VisibilityBeta
Overall Score
D24
Category Rank
#1 of 2
AI Consensus
61%
Trend
up
Per Platform
ChatGPT
19
Perplexity
31
Gemini
18

About

Lyell Immunopharma is a clinical-stage cell therapy company founded in 2018 by Rick Klausner and publicly traded on Nasdaq. The company focuses on next-generation CAR-T therapies that address the key limitations of first-generation products, particularly the exhaustion and dysfunction of engineered T cells that limits efficacy especially against solid tumors. Lyell has developed proprietary T cell reprogramming technologies including gene overexpression approaches that maintain T cell stemness and fitness during manufacturing and after infusion. The company is applying these technologies to both hematological malignancies and solid tumors in a pipeline of clinical programs. Lyell has established a research collaboration with GlaxoSmithKline to combine cell therapy expertise. While first-generation CAR-T products have demonstrated remarkable responses in blood cancers, Lyell is focused on the much larger unmet need in solid tumors where current CAR-T therapies have shown limited efficacy. The company represents the scientific evolution of the cell therapy field toward more durable and broadly applicable treatments.

Full profile

IBM

LeaderEnterprise Software

General

Armonk NY hybrid cloud and enterprise AI (NYSE: IBM) at $62.8B revenue; $6B+ generative AI bookings, record $12.7B free cash flow 2024, DataStax acquisition for watsonx vector database competing with Microsoft Azure for enterprise AI.

AI VisibilityBeta
Overall Score
A80
Category Rank
#56 of 1158
AI Consensus
67%
Trend
up
Per Platform
ChatGPT
74
Perplexity
71
Gemini
84

About

International Business Machines Corporation (IBM) is an Armonk, New York-based global technology and consulting company — publicly traded on the New York Stock Exchange (NYSE: IBM) as an S&P 500 component — providing hybrid cloud infrastructure, artificial intelligence software, and enterprise IT consulting through approximately 270,300 employees in 170 countries with $62.8 billion in annual revenue. Founded on June 16, 1911, as Computing-Tabulating-Recording Company through a merger orchestrated by financier Charles Ranlett Flint, renamed IBM in 1924 under Thomas Watson Sr., IBM has undergone multiple strategic transformations over its 110+ year history: building the System/360 mainframe platform (1964), launching the IBM PC (1981), selling the PC division to Lenovo (2005, $1.75B), and completing the $34 billion Red Hat acquisition (2019) that repositioned IBM as a hybrid cloud platform company. CEO Arvind Krishna (appointed April 2020) has focused IBM's strategy on three areas: hybrid cloud (powered by Red Hat OpenShift, the enterprise Kubernetes platform), AI (the watsonx platform for enterprise AI model development and deployment), and enterprise consulting. Under Krishna, IBM recorded $12.7 billion in free cash flow in 2024 (a company record), surpassed $6 billion in generative AI bookings since June 2023, and saw the stock price double — trading at all-time highs through 2024-2025. IBM announced the DataStax acquisition in 2025 to deepen watsonx's data layer with AstraDB (vector database for AI applications), DataStax Enterprise (Apache Cassandra), and Langflow (low-code AI agent development).

Full profile

AI Visibility Head-to-Head

24
Overall Score
80
#1
Category Rank
#56
61
AI Consensus
67
up
Trend
up
19
ChatGPT
74
31
Perplexity
71
18
Gemini
84
17
Claude
74
28
Grok
81

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.